Jose Aguirre, MD
Family Medicine · Houston, TXNPI 1205086311
Payments from drug & device makers
Across 779 payments — averaging $17.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$3K
- Novo Nordisk$1K
- Bayer$1K
- Boehringer Ingelheim$911
- Lilly USA, LLC$841
- Johnson & Johnson$666
- plus $5K from 28 others
What the payments were for
- Food & beverage$13,234100%
- Education$60%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 117 | $3,309 |
| Novo Nordisk | 103 | $1,347 |
| Bayer | 82 | $1,116 |
| Boehringer Ingelheim | 44 | $911 |
| Lilly USA, LLC | 56 | $841 |
| Johnson & Johnson | 45 | $666 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 46 | $613 |
| AbbVie(2 entities) | 35 | $532 |
| Amgen(2 entities) | 32 | $500 |
| GSK | 32 | $493 |
| Astellas Pharma US Inc | 28 | $458 |
| Sumitomo Pharma America, Inc. | 29 | $385 |
| Endo Pharmaceuticals Inc. | 28 | $342 |
| Nestle Healthcare Nutrition Inc. | 18 | $295 |
| Amarin Pharma, Inc. | 13 | $215 |
| Aimmune Therapeutics, Inc. | 12 | $206 |
| Esperion Therapeutics, Inc. | 12 | $186 |
| Mannkind Corporation | 13 | $140 |
| Boston Scientific | 2 | $132 |
| Merck | 8 | $126 |
| Abbott | 3 | $54 |
| Genentech USA, Inc. | 3 | $48 |
| Novartis | 2 | $44 |
| Arbor Pharmaceuticals, Inc. | 3 | $43 |
| Theratechnologies Inc. | 2 | $42 |
| Kowa Pharmaceuticals America, Inc. | 2 | $31 |
| Redhill Biopharma Inc. | 2 | $29 |
| Optinose US, Inc. | 1 | $23 |
| Pfizer | 1 | $23 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $23 |
| Phathom Pharmaceuticals, Inc. | 1 | $21 |
| ARS Pharmaceuticals Operations, Inc. | 1 | $16 |
| Paratek Pharmaceuticals, Inc. | 1 | $15 |
| Acerus Pharmaceuticals Corporation | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$13,240 in reported general payments places this provider in the 95th percentile of 8,760 family medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 180 | $224,608 |
| JardianceEmpagliflozin | 120 | $181,352 |
| TradjentaLinagliptin | 107 | $149,636 |
| JanuviaSitagliptin Phosphate | 102 | $146,601 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 94 | $138,479 |
| Xigduo XrDapaglifloz Propaned/Metformin | 123 | $137,707 |
| KerendiaFinerenone | 65 | $94,702 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 69 | $92,610 |
| MounjaroTirzepatide | 47 | $79,478 |
| GlyxambiEmpagliflozin/Linagliptin | 52 | $76,435 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 46 | $72,260 |
| GemtesaVibegron | 48 | $70,066 |
| LinzessLinaclotide | 41 | $64,196 |
| ProliaDenosumab | 29 | $50,030 |
| Trijardy XrEmpaglifloz/Linaglip/Metformin | 42 | $47,586 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta, Synjardy Xr, Glyxambi, Trijardy Xr | $911 | $610,120426 claims |
| MerckJanuvia, Janumet Xr, Janumet | $126 | $254,985189 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $3,309 | $254,163203 claims |
| Lilly USA, LLCMounjaro, Trulicity | $841 | $116,06667 claims |
| BayerKerendia | $1,116 | $94,70265 claims |
| Novo NordiskOzempic, Rybelsus | $1,347 | $76,88140 claims |
| GSKTrelegy Ellipta | $493 | $72,26046 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $385 | $70,06648 claims |
| AbbVieLinzess | $532 | $64,19641 claims |
| AmgenProlia | $500 | $50,03029 claims |
| Johnson & JohnsonXarelto | $666 | $42,39337 claims |
| PfizerEliquis | $23 | $25,03918 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,760 family medicine providers in Texas.
Other family medicine in Houston
- Lisa HollowayHouston$30.1M
- Veronica FragosoHouston$24.5M
- Bonnie ColvilleHouston$19.6M
- Oscar de ValleHouston$12.8M
- van TranHouston$11M
- Joe PouzarHouston$10.7M
- Aalia Al-BarwaniHouston$6.8M
- Terence ChangHouston$3.3M
- Douglas DenhamSan Antonio$68.5M
- Vicki MillerPasadena$58.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.